Neurizon expands ALS trial arm after recruitment runs ahead of plan

Australian clinical-stage biotech Neurizon Therapeutics (ASX: NUZ) is expanding the NUZ-001 arm of the HEALEY ALS Platform Trial after recruitment ran faster than expected.

Regimen I will now enroll 240 participants, up from 160 previously. The company said the larger cohort is designed to preserve statistical power for the trial’s primary endpoint, in line with the study’s original assumptions.

The amended design will include 180 participants receiving NUZ-001 and 60 placebo controls. Neurizon said the expansion should also allow more useful analysis of patient subgroups and biomarkers.

The company said the expansion will not change its funding requirements through study completion. 

Sergio Duchini, interim executive chairman of Neurizon, said the decision “reflects our considerable confidence in NUZ-001” and should strengthen the program as it moves toward a potentially pivotal readout.

High unmet need

Amyotrophic lateral sclerosis (ALS) remains one of the harder areas of neurology drug development. The disease has few approved medicines, trial outcomes can be difficult to read, and investors have learned to be wary of small or early-stage signals.

The HEALEY ALS Platform Trial has become an important testing ground in the field. Its master protocol allows different investigational drugs to be assessed using shared trial infrastructure, potentially making studies faster and more efficient than stand-alone programs.

For Neurizon, the expanded arm gives NUZ-001 a cleaner shot at producing interpretable data. The larger control group means the company can rely less on placebo data from other regimens, which may matter if the results are later used in regulatory or partnering discussions.

Market estimates vary, but recent forecasts put the global ALS treatment market at roughly $1 billion in 2026, with growth expected as diagnosis, treatment access and new product development improve.

The approved treatment landscape is thin. Biogen (Nasdaq: BIIB) markets Qalsody (tofersen) for a genetic form of ALS linked to SOD1 mutations, while Radicava (edaravone) is available for broader ALS use.

Shionogi (TYO: 4507) agreed in 2025 to acquire global rights to the Radicava business from Tanabe Pharma, reflecting continued interest in a field where approved products are scarce.